TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03862222

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Evaluation
Description: Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological Evaluation
Description: Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.

Intervention type: GENETIC
Intervention: APOE genotyping
Description: APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.

Intervention type: GENETIC
Intervention: APOE genotyping
Description: APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.

Intervention type: GENETIC
Intervention: APOE genotyping
Description: APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.

Intervention type: GENETIC
Intervention: APOE genotyping
Description: APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.

Intervention type: OTHER
Intervention: blood draw
Description: Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis

Intervention type: OTHER
Intervention: blood draw
Description: Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis

Intervention type: OTHER
Intervention: blood draw
Description: Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis

Intervention type: OTHER
Intervention: blood draw
Description: Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis

Intervention type: OTHER
Intervention: Gait Assessment
Description: Gait assessment will be conducted by trained researcher

Intervention type: OTHER
Intervention: Gait Assessment
Description: Gait assessment will be conducted by trained researcher

Intervention type: OTHER
Intervention: Gait Assessment
Description: Gait assessment will be conducted by trained researcher

Intervention type: OTHER
Intervention: Gait Assessment
Description: Gait assessment will be conducted by trained researcher

Intervention type: OTHER
Intervention: Actigraphy
Description: Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.

Intervention type: OTHER
Intervention: Actigraphy
Description: Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
Study: NCT04080492

Intervention type: OTHER
Intervention: QOL Survey
Description: The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
Study: NCT01977248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Affect Relationship-based Therapy (SMART)
Description: The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
Study: NCT03879993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Resistance training 3 times per week (45-60 minutes of resistance training)
Study: NCT03862222

Intervention type: OTHER
Intervention: Actigraphy
Description: Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.

Intervention type: OTHER
Intervention: Actigraphy
Description: Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
Study: NCT04472637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 10 mg, as one tablet /day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 24 weeks)
Study: NCT00555568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recovery oriented mental health peer support group
Description: This is a recovery-focused mental health education and support group led by peer facilitators

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: recovery-oriented mental health clinician-led group
Description: This is a recovery-focused mental health education and support group led by a mental health clinician
Study: NCT03636308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nanoparticle albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
Study: NCT02687360

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS treatment
Description: In the active treatment, magnetic power output will be delivered to the participants through the coils.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS treatment
Description: The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
Study: NCT01726816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol 250mg/day
Description: Probucol 250mg + Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol 500mg/day
Description: Probucol 500mg + Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Probucol matching placebo
Study: NCT04486989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular Conditioning Protocol
Description: Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voice Production Exercises
Description: Participants will be randomized to either one of the treatment arms to receive treatment for a period of 4 weeks.
Study: NCT02031198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AADvac1
Description: Active immunization against pathological Alzheimer's disease tau protein
Study: NCT01385319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent implantation
Description: After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zotarolimus eluting stent
Description: After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month.
Study: NCT03380000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice placebo
Description: This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
Study: NCT00947934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
Study: NCT00106340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Study: NCT05633680

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood sampling for circulating tumor cells
Description: Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.

Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood sampling for circulating tumor cells
Description: Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.
Study: NCT00002657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: 5 mg/m\^2
Study: NCT02144415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-1020 400 mg
Description: 4 x EB-1020 100-mg capsules, and 4 matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB-1020 800 mg
Description: 8 x EB-1020 100-mg capsules
Study: NCT00002657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: 3.0 x 10\^6 IU/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 650 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 300 mg/m\^2
Study: NCT02144415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine 150 mg
Description: 3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-amphetamine 40 mg
Description: 4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
Study: NCT00002657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 120 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 120 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Simple excision, for those patients who have resectable disease after initial immunosuppression.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: For treatment of localized disease that remains after initial immunosuppression.
Study: NCT01349296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + BIBF 1120
Description: Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
Study: NCT02144415

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 x matching placebo capsules
Study: NCT00491816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib with neoadjuvant chemotherapy
Description: 150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
Study: NCT03268369

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI of the brain
Description: to eliminate a structural intra-cerebral lesion
Study: NCT00719992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography
Description: effect of level of HS-CRP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: effect of level of HS-CRP
Study: NCT02162654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
Study: NCT02691481

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oatmeal breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ultra Glucose Control formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ultra Glucose Control formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ultra Glucose Control formula
Study: NCT01626534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600mg loading dose then 75mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trigagrelor
Description: 180 mg loading dose then 90 mg Twice a day
Study: NCT03507192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle relaxation using full body massage machine
Description: Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
Study: NCT04447924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bif195
Description: Daily intake of Bif195 dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of Placebo
Study: NCT00435149

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Patient will have carpal tunnel release surgery and will be put in a splint after surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
Study: NCT06276842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block
Description: Administration of a local anesthetic agent around the inferior alveolar nerve to achieve anesthesia in the mandibular region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Infiltration
Description: Administration of a local anesthetic agent into the tissue adjacent to the tooth being treated to achieve localized anesthesia.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Inferior Alveolar Nerve Block and Buccal Infiltration
Description: Utilization of both the Inferior Alveolar Nerve Block and Buccal Infiltration techniques simultaneously for anesthesia in the mandibular region.
Study: NCT03066297

Intervention type: PROCEDURE
Intervention: Extent of pulmonary resection
Description: Extent of pulmonary resection selected based on the institutional decision-making algorithm

Intervention type: PROCEDURE
Intervention: Extent of pulmonary resection
Description: Extent of pulmonary resection selected based on the institutional decision-making algorithm
Study: NCT03268369

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI of the brain
Description: to eliminate a structural intra-cerebral lesion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI of the brain
Description: to eliminate a structural intra-cerebral lesion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI of the brain
Description: to eliminate a structural intra-cerebral lesion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET scan [18F]F-A-85380
Description: exam performed after iv injection of 200 MBq \[18F\]F-A-85380

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]F-A-85380
Description: exam performed after iv injection of 200 MBq \[18F\]F-A-85380

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]F-A-85380
Description: exam performed after iv injection of 200 MBq \[18F\]F-A-85380
Study: NCT00809861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: volar locking plating
Description: open reduction and internal fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external immobilisation
Description: closed reduction and external fixation
Study: NCT03268369

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]F-A-85380
Description: exam performed after iv injection of 200 MBq \[18F\]F-A-85380
Study: NCT02883920

Intervention type: OTHER
Intervention: Allergy and respiratory functional tests
Study: NCT01375738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en Y gastrojejunostomy
Description: After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25\~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30\~40cm from the new gastric-jejunal junction.
Study: NCT00106340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT01375738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroduodenostomy
Description: After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
Study: NCT02162654

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham preconditioning
Description: The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
Study: NCT02819531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational atherectomy
Description: Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
Study: NCT01135745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reclaim® Deep Brain Stimulation
Description: Implant of leads in pre-defined brain area; implant of neurostimulators
Study: NCT02819531

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital atherectomy
Description: Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scoring balloon system
Description: Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
Study: NCT01833858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose HCG
Description: Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
Study: NCT03268369

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]F-A-85380
Description: exam performed after iv injection of 200 MBq \[18F\]F-A-85380

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET scan [18F]FDG
Description: exam performed after iv injection of 200 MBq \[18F\]FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]FDG
Description: exam performed after iv injection of 200 MBq \[18F\]FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET scan [18F]FDG
Description: exam performed after iv injection of 200 MBq \[18F\]FDG
Study: NCT03498092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-Dexmedetomidine
Description: isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: Normal saline in a volume of 0.5 ml/kg